



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07C 311/21, 311/13, C07D 295/26, 211/96, 213/74, 307/81, 215/58, A61K 31/18, 31/4965, 31/445, 31/343, 31/472, A61P 7/00, 11/00, 29/00, 35/00	A1	(11) International Publication Number: WO 00/56704 (43) International Publication Date: 28 September 2000 (28.09.00)
(21) International Application Number: PCT/GB00/01076 (22) International Filing Date: 22 March 2000 (22.03.00) (30) Priority Data: 9906585.6 22 March 1999 (22.03.99) GB 9927782.4 24 November 1999 (24.11.99) GB (71) Applicant (for all designated States except US): DARWIN DISCOVERY LIMITED [GB/GB]; Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): OWEN, David, Alan [GB/GB]; Darwin Discovery Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). BAXTER, Andrew, Douglas [GB/GB]; Darwin Discovery Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). WATSON, Robert, John [GB/GB]; Darwin Discovery Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). BATTY, Duncan [GB/GB]; Darwin Discovery Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB).	(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB). (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES		
(57) Abstract Compounds (many of which are new) that have utility in the treatment of a condition associated with matrix metalloproteinase, ADAM or ADAM-TS enzymes, a condition that is mediated by TNF α or a condition involving a membrane-shedding event that is mediated by a metalloproteinase, are of formula (I): $(B)_2N-X-(CH_2)_m-W-(CR^1R^2)_n-COY$, wherein $n=0$ or 1 ; $m=0$ or 1 ; X is $S(O)_{1-2}$; Y is OH or $NHOH$; W is aryl or heteroaryl; and the other groups are as defined herein.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES

Field of the Invention

This invention relates to hydroxamic and carboxylic acid derivatives, and to their use in medicine.

5 Background to the Invention

10 Metalloproteinases, including matrix metalloproteinase (MMP), (human fibroblast) collagenase, gelatinase and TNF α convertase (TACE), and their modes of action, and also inhibitors thereof and their clinical effects, are described in WO-A-96/11209, WO-A-97/12902 and WO-A-97/19075, the contents of which are incorporated herein by reference. MMP inhibitors may also be useful in the inhibition of other mammalian metalloproteinases such as the ADAM or ADAM-TS families. Members of the ADAM family include TNF α convertase (TACE) and ADAM-10, which can cause the release of TNF α from cells, and others, which have been demonstrated to be expressed by human articular cartilage cells and also involved in the destruction of myelin basic protein, a
15 phenomenon associated with multiple sclerosis.

Compounds which have the property of inhibiting the action of metalloproteinases involved in connective tissue breakdown, such as collagenase, stromelysin and gelatinase, have been shown to inhibit the release of TNF α both *in vitro* and *in vivo*. See Gearing *et al* (1994), Nature 370:555-557; McGeehan *et al* (1994), Nature 370:558-561; GB-A-2268934; and WO-A-93/20047. All of these reported inhibitors contain a hydroxamic acid zinc-binding group, as do the imidazole-substituted compounds disclosed in WO-A-95/23790. Other compounds that inhibit MMP and/or TNF α are described in WO-A-95/13289, WO-A-96/11209, WO-A-96/035687, WO-A-96/035711, WO-A-96/035712 and WO-A-96/035714.


25 WO-A-98/38859 discloses sulfonyl-divalent aryl/heteroaryl hydroxamic compounds as MMP inhibitors. In addition to the claimed compounds, it discloses related compounds including N-hydroxy-2-[[4-(phenylmethyl)-1-piperidinyl]sulfonyl]benzamide, as having inferior properties.

30 Probenecid, i.e. 4-[(dipropylamino)sulfonyl]benzoic acid, has long been known as a uricosuric agent; see US-A-2608507. Certain metabolites are reported by Israeli *et al*, J. Med. Chem. 15(7):709-13 (1972).

Summary of the Invention

The invention encompasses novel compounds of formula (I) which are useful inhibitors of matrix metalloproteinase, ADAM or ADAMTS enzymes, and which are useful for the treatment of diseases mediated by those enzymes and/or TNF α mediated diseases, including degenerative diseases and certain cancers.

Novel compounds according to the invention are of the general type represented by formula (I):



10

wherein

$n = 0-1$;

$m = 0-1$;

X is S(O)₁₋₂;

15

Y is OH or NHOH;

W is aryl or heteroaryl;

R^1 is H, OR⁷ or a group (optionally substituted with R³) selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, C₁₋₆ alkyl-aryl, heteroaryl, C₁₋₆ alkyl-heteroaryl, cycloalkyl, C₁₋₆ alkyl-cycloalkyl, heterocycloalkyl, C₁₋₆ alkyl-heterocycloalkyl; and

20

R^2 is H or C₁₋₆ alkyl;

or CR¹R² is cycloalkyl or heterocycloalkyl optionally substituted with R³ or a group (optionally substituted with R³) selected from C₁₋₆ alkyl, aryl, C₁₋₆ alkyl-aryl, heteroaryl, C₁₋₆ alkyl-heteroaryl;

R³ is OR⁷, COR⁷, CO₂R⁸, CON(R⁷)₂, N(R⁷)₂, NR⁷COR⁷, NR⁷CON(R⁷)₂, NR⁷CO₂R⁸, NR⁷SO₂R⁸, S(O)₀₋₂R⁸, SO₂N(R⁷)₂ or cycloimidyl (optionally substituted with R⁴);

25

R⁴ is C₁₋₆ alkyl;

B is H or a group (optionally substituted with R⁵ or R⁶) selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, aryl, C₁₋₆ alkyl-aryl, heteroaryl, C₁₋₆ alkyl-heteroaryl, cycloalkyl, C₁₋₆ alkyl-cycloalkyl, heterocycloalkyl, C₁₋₆ alkyl-heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl; and each instance of B may be the same or different;

30

R^5 is a group (optionally substituted with R^6) selected from C_{1-6} alkyl, aryl, C_{1-6} alkyl-aryl, heteroaryl, C_{1-6} alkyl-heteroaryl, cycloalkyl, C_{1-6} alkyl-cycloalkyl, heterocycloalkyl and C_{1-6} alkyl-heterocycloalkyl;

or B-N-B is heterocycloalkyl optionally substituted with R^5 , R^6 , =O or =NOR⁵;

5 R^6 is a group selected from $N(R^7)_2$, NR^7COR^7 , $NR^7CON(R^7)_2$, $NR^7CO_2R^8$, $NR^7SO_2R^8$, OR^7 , COR^7 , CO_2R^4 , $CON(R^7)_2$, $S(O)_{0-2}R^8$, and $SO_2N(R^7)_2$;

R^7 is H or a group selected from C_{1-6} alkyl, aryl, C_{1-6} alkyl-aryl, heteroaryl, C_{1-6} alkyl-heteroaryl, cycloalkyl, C_{1-6} alkyl-cycloalkyl, heterocycloalkyl and C_{1-6} alkyl-heterocycloalkyl, wherein said group is optionally substituted with R^8 , COR^8 , $SO_{0-2}R^8$, CO_2R^8 , OR^8 , $CONR^4R^8$, NR^4R^8 , or $SO_2NR^4R^8$ and for each case of $N(R^7)_2$ the R^7 groups are the same or different or $N(R^7)_2$ is heterocycloalkyl optionally substituted with R^8 , COR^8 , $SO_{0-2}R^8$, CO_2R^8 , OR^8 , $CONR^4R^8$, NR^4R^8 , or $SO_2NR^4R^8$;

R^8 is C_{1-6} alkyl, aryl, C_{1-6} alkyl-aryl, heteroaryl or C_{1-6} alkyl-heteroaryl; and the salts, solvates, hydrates, N-oxides, protected amino, protected carboxy and
15 protected hydroxamic acid derivatives thereof.

Many compounds of formula I are new.

Description of the Invention

Preferred compounds of the invention are those wherein X is SO_2 ; Y is NHOH and/or B-N-B is optionally substituted heterocycloalkyl. Other preferences are defined in
20 the subclaims.

It will be appreciated that the compounds according to the invention can contain one or more asymmetrically substituted carbon atoms. The presence of one or more of these asymmetric centres in a compound of formula (I) can give rise to stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers,
25 including enantiomers and diastereomers, and mixtures including racemic mixtures thereof.

It will further be appreciated that the compounds according to the invention may contain an oxime. This oxime can give rise to geometrical isomers, and in each case the invention is to be understood to extend to all such isomers and mixtures thereof.

As used in this specification, alone or in combination, the term " C_{1-6} alkyl" refers
30 to straight or branched chain alkyl moiety having from one to six carbon atoms, including for example, methyl, ethyl, propyl, isopropyl, butyl, *tert*-butyl, pentyl, hexyl and the like.

The term " C_{2-6} alkenyl" refers to a straight or branched chain alkyl moiety having two to six carbon atoms and having in addition one double bond, of either E or Z

stereochemistry where applicable. This term would include for example, vinyl, 1-propenyl, 1- and 2- butenyl, 2- methyl-2-propenyl etc.

The term "C₂₋₆ alkynyl" refers to a straight or branched chain alkyl moiety having two to six carbon atoms and having in addition one triple bond. This term would include
5 for example, ethynyl, 1-propynyl, 1- and 2- butynyl, 1- methyl-2-butynyl etc.

The term "cycloalkyl" refers to a saturated alicyclic moiety having from three to eight, e.g. 3-6, carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and bicyclo[2.2.1]heptanyl.

The term "cycloalkenyl" refers to an alicyclic moiety having from three to eight
10 carbon atoms and having in addition one double bond. This term includes, for example, cyclopentenyl, cyclooctenyl and bicyclo[2.2.1]heptenyl.

The term "heterocycloalkyl" refers to a saturated heterocyclic moiety having from two to eight, e.g. 2-6, carbon atoms and one or more heteroatom from the group N, O, S (or oxidised versions thereof) which may be optionally benzofused at any available
15 position. This includes, for example, azetidiny, pyrrolidiny, tetrahydrofuranyl, piperidiny, benzodioxole and 8-oxabicyclo[3.2.1]octane.

The term "heterocycloalkenyl" refers to an alicyclic moiety having from three to eight carbon atoms and one or more heteroatoms selected from N, O, S and oxidised versions thereof, and having in addition one double bond. This term includes, for example,
20 dihydropyranyl and 8-oxabicyclo[3.2.1]octene.

The term "aryl" refers to an aromatic carbocyclic radical having a single ring or two condensed rings, optionally substituted with an aryl group substituent. This term includes, for example, phenyl and naphthyl.

The term "heteroaryl" refers to aromatic ring systems of five to ten atoms of which
25 at least one atom is selected from O, N and S, and optionally substituted with an aryl group substituent. This term includes, for example, furanyl, thiophenyl, pyridyl, indolyl and quinolyl.

The term "aryl group substituent" refers to a substituent chosen from halogen, CN, CF₃, CHF₂, CH₂F, OCF₃, OCHF₂, OCH₂F and NO₂. The substituent may also be OC₁₋₆
30 alkyl.

The term "halogen" means fluorine, chlorine, bromine or iodine.

The term "benzofused" refers to the addition of a benzene ring sharing a common bond with the defined ring system.

The term "cycloimidyl" refers to a saturated ring of five to ten atoms containing the atom sequence $-C(=O)NC(=O)-$. The ring may be optionally benzofused at any available position. Examples include succinimidoyl, phthalimidoyl and hydantoinyl.

The term "optionally substituted" means optionally substituted with one or more
5 of the groups specified, at any available position or positions.

The terms "protected amino", "protected carboxy" and "protected hydroxamic acid" mean amino, carboxy and hydroxamic acid groups which can be protected in a manner familiar to those skilled in the art. For example, an amino group can be protected by a benzyloxycarbonyl, *tert*-butoxycarbonyl, acetyl or like group, or may be in the
10 form of a phthalimido or like group. A carboxyl group can be protected in the form of a readily-cleavable ester such as the methyl, ethyl, benzyl or *tert*-butyl ester. A hydroxamic acid may be protected as either N or O-substituted derivatives, such as O-benzyl or O-*tert*-butyldimethylsilyl.

Salts of compounds of formula (I) include pharmaceutically-acceptable salts, for
15 example acid addition salts derived from inorganic or organic acids, such as hydrochlorides, hydrobromides, p-toluenesulphonates, phosphates, sulphates, perchlorates, acetates, trifluoroacetates, propionates, citrates, malonates, succinates, lactates, oxalates, tartrates and benzoates.

Salts may also be formed with bases. Such salts include salts derived from
20 inorganic or organic bases, for example alkali metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

When the "protected carboxy" group in compounds of the invention is an esterified carboxyl group, it may be a metabolically-labile ester of formula CO_2R^9 where R^9 may be
25 an ethyl, benzyl, phenethyl, phenylpropyl, α or β -naphthyl, 2,4-dimethylphenyl, 4-*tert*-butylphenyl, 2,2,2-trifluoroethyl, 1-(benzyloxy)benzyl, 1-(benzyloxy)ethyl, 2-methyl-1-propionyloxypropyl, 2,4,6-trimethylbenzyloxymethyl or pivaloylmethyl group.

Compounds of the general formula (I) may be prepared by any suitable method known in the art and/or by the following processes.

30 It will be appreciated that, where a particular stereoisomer of formula (I) is required, the synthetic processes described herein may be used with the appropriate homochiral starting material and/or isomers may be resolved from mixtures using conventional separation techniques (e.g. HPLC).

The compounds according to the invention may be prepared by the following process. In the description and formulae below the groups R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , W, B, X and Y are as defined above, except where otherwise indicated. It will be appreciated that functional groups, such as amino, hydroxyl or carboxyl groups, present in the various compounds described below, and which it is desired to retain, may need to be in protected form before any reaction is initiated. In such instances, removal of the protecting group may be the final step in a particular reaction. Suitable protecting groups for such functionality will be apparent to those skilled in the art. For specific details see Greene *et al*, "Protective Groups in Organic Synthesis", Wiley Interscience.

10 A process for preparing compounds of general formula (I) comprises acylating an amine of formula B_2NH (II) with an acylating agent of formula $Z-X-(CH_2)_m-W-(CR^1R^2)_n-COY$ (III) wherein Z represents a suitable leaving group (e.g. a halogen such as chlorine), and Y is OH or NHOH or protected forms thereof such as OR^{10} (where R^{10} is a suitable protecting group such as benzyl or *tert*-butyl) or $NHOR^{11}$ (where R^{11} is a suitable protecting group such as benzyl, *tert*-butyl or *tert*-butyldimethylsilyl).

15 Acylating agents of formula (III) where $m = 0$ and X is SO_2 , if not available commercially, may be prepared in a two-step process involving the sulfonation of an aromatic group of formula $W-(CR^1R^2)_n-COY$ (IV) to give a sulfonic acid $HO-SO_2-W-(CR^1R^2)_n-COY$ (V) followed by activation to (III). Many compounds of formula (IV) are available, or may be prepared by methods known to those skilled in the art.

20 Acylating agents of formula (III) where $m = 1$ and X is SO_2 may be prepared from compounds of formula $R^{12}S-CH_2-W-(CR^1R^2)_n-COY$ (VI), where R^{12} is H or a suitable labile group such as acetyl, by treatment with chlorine in an appropriate solvent such as water at an appropriate temperature such as 0 °C. Acylating agents of formula (III) where X = SO may be prepared from compound (VI) by treatment with SO_2Cl_2 and acetic anhydride in an appropriate solvent such as dichloromethane at an appropriate temperature such as 0 °C.

25 Sulfanyl compounds of formula (VI) may be prepared readily by alkylation of a compound $R^{12}SH$ with an alkylating agent of the form $Z^A-CH_2-W-(CR^1R^2)_n-COY$ (VII), where Z^A is a leaving group (e.g. a halogen such as bromine, or an alkylsulfonate ester such as methanesulfonate). Many compounds of the form (VII) are available commercially, or may be prepared by standard chemistry known to those skilled in the art from materials available commercially.

Amines of the structure depicted in formula (II) are commercially available or may be prepared by standard aromatic, heteroaromatic or other chemistry known to those skilled in the art, from commercially available materials.

Compounds of formula (I) may also be prepared by interconversion of other compounds of formula (I). Thus, for example, compound of formula (I) where X=SO₂ may be prepared from a compound of formula (I) where X=SO by oxidation with, for example sodium periodate and ruthenium chloride trihydrate in an appropriate solvent, for example acetonitrile-tetrachloromethane-water. Hydroxamic acids (Y=NHOH) of general formula (I) may be prepared from carboxylic acids (Y=OH) of formula (I) using methods known to those skilled in the art.

Similarly, intermediates of any appropriate formula may be prepared by the interconversion of other compounds of the same formula. Thus, for example, a compound of formula (VI) where R² is not H may be prepared from a compound of formula (VI) where R² is H by reaction with a compound R²Z (where Z is as defined above) in the presence of a strong base such as lithium diisopropylamide in an inert solvent such as tetrahydrofuran.

Any mixtures of final products or intermediates obtained can be separated on the basis of the physico-chemical differences of the constituents, in known manner, into the pure final products or intermediates, for example by chromatography, distillation, fractional crystallization, or by formation of a salt if appropriate or possible under the circumstances.

The compounds according to the invention exhibit *in vitro* inhibiting activities with respect to the stromelysin, collagenase, gelatinase, ADAM or ADAM-TS enzymes. Compounds according to the invention may also exhibit *in vitro* inhibition of membrane-shedding events known to be mediated by metalloproteinases, for example, α -APP, ACE, TGF- α , TNF- α , Fas ligand, selectins, TNFR-I, TNFR-II, CD30, IL-6R, CD43, CD44, CD16-I, CD16-II, Folate receptor, CD23, or IL-1RII.

The activity and selectivity of the compounds may be determined by use of the appropriate enzyme inhibition test, for example as described in Examples A-M of WO-A-98/05635, by the assay for the inhibition of CD23 shedding described in WO-A-99/24399, or by the following assay of TNF RI shedding.

The potency of the compounds of general formula (I) to act as inhibitors of the production of TNF RI is determined using the following procedure. A 100 μ M solution of

the inhibitor being tested or dilutions thereof is incubated at 37° C in an atmosphere of 5% CO₂ with peripheral blood mononuclear cells (PBMC). PBMC are isolated from buffy coats by standard procedures using Ficoll. A 100µM solution of the inhibitor being tested or dilutions thereof is incubated for 22 hours at 37° C in an atmosphere of 5% CO₂ with
5 1 x 10⁶/ml PBMC stimulated with LPS. The cells are centrifuged down and the supernatant is assayed for TNF RI using a commercially available ELISA kit (R & D Systems). The activity in the presence of 0.1mM inhibitor or dilutions thereof is compared to activity in a control devoid of inhibitor and results reported as that inhibitor concentration effecting 50% inhibition of the production of TNF RI.

10 This invention also relates to a method of treatment for patients (including man and/or mammalian animals raised in the dairy, meat or fur industries or as pets) suffering from disorders or diseases which can be attributed to stromelysin as previously described, and more specifically, a method of treatment involving the administration of the matrix metalloproteinase inhibitors of formula (I) as the active constituents.

15 Accordingly, the compounds of formula (I) can be used among other things in the treatment of osteoarthritis and rheumatoid arthritis, and in diseases and indications resulting from the over-expression of these matrix metalloproteinases such as found in certain metastatic tumour cell lines.

As mentioned above, compounds of formula (I) are useful in human or veterinary
20 medicine since they are active as inhibitors of TNF and MMPs. Accordingly in another aspect, this invention concerns:

a method of management (by which is meant treatment or prophylaxis) of disease or conditions mediated by TNF and/or MMPs in mammals, in particular in humans, which method comprises administering to the mammal an effective, amount of a compound of
25 formula (I) above, or a pharmaceutically acceptable salt thereof; and

a compound of formula (I) for use in human or veterinary medicine, particularly in the management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by TNF and/or MMPs; and

the use of a compound of formula (I) in the preparation of an agent for the
30 management (by which is meant treatment or prophylaxis) of diseases or conditions mediated by TNF and/or MMPs.

The disease or conditions referred to above include inflammatory diseases, autoimmune diseases, cancer, cardiovascular diseases, diseases involving tissue breakdown

such as rheumatoid arthritis, osteoarthritis, osteoporosis, neurodegeneration, Alzheimer's disease, stroke, vasculitis, Crohn's disease, ulcerative colitis, multiple sclerosis, periodontitis, gingivitis and those involving tissue breakdown such as bone resorption, haemorrhage, coagulation, acute phase response, cachexia and anorexia, acute infections, HIV infections, fever, shock states, graft versus host reactions, dermatological conditions, surgical wound healing, psoriasis, atopic dermatitis, epidermolysis bullosa, tumour growth, angiogenesis and invasion by secondary metastases, ophthalmological disease, retinopathy, corneal ulceration, reperfusion injury, migraine, meningitis, asthma, rhinitis, allergic conjunctivitis, eczema, anaphylaxis, restenosis, congestive heart failure, endometriosis, atherosclerosis, endosclerosis and aspirin-independent anti-thrombosis.

Compounds of formula (I) may also be useful in the treatment of pelvic inflammatory disease (PID), age-related macular degeneration and cancer-induced bone resorption. Further, they can be used in the treatment of lung diseases, e.g. selected from cystic fibrosis, adult respiratory distress syndrome (ARDS), emphysema, bronchitis obliterans-organising pneumonia (BOOP), idiopathic pulmonary fibrosis (PIF), diffuse alveolar damage, pulmonary Langerhan's cell granulomatosis, pulmonary lymphangiomyomatosis (LAM) and chronic obstructive pulmonary disease (COPD).

For the treatment of rheumatoid arthritis, osteoarthritis, and in diseases and indications resulting from the over-expression of matrix metalloendoproteinases such as found in certain metastatic tumour cell lines or other diseases mediated by the matrix metalloendoproteinases or increased TNF production, the compounds of formula (I) may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats etc, the compounds of the invention are effective in the treatment of humans.

The pharmaceutical composition containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of

sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert
5 diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the
10 gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the US Patents 4,256,108; 4,166,452; and 4,265,874, to form osmotic therapeutic tablets for control release.

15 Formulations for oral use may also be presented as hard gelatin capsules where in the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active materials in admixture with excipients
20 suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example
25 polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene with partial esters derived from fatty acids and hexitol anhydrides, for
30 example polyoxyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set
5 forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a
10 dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified, for example sweetening, flavouring and colouring agents may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis
15 oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally- occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soya bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate and condensation products of the said partial esters with ethylene oxide, for example
20 polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may
25 be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be in a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
30 Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland

fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compounds of formula (I) may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, jellies, solutions or suspensions, etc containing the compounds of Formula (I) are employed. For the purposes of this specification, topical application includes mouthwashes and gargles.

Dosage levels of the order of from about 0.05 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above- indicated conditions (about 2.5 mg to about 7 g per patient per day). For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day (about 0.5 mg to about 3.5 g per patient per day).

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may vary from about 5 to about 95% of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of active ingredient.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

The following Examples illustrate compounds of the invention.

Intermediate 1 4-(4-Hydroxyphenyl)piperazine-1-carboxylic acid *tert*-butyl ester

To a stirred solution of 1-(4-hydroxyphenyl)piperazine (25g) in dichloromethane (150ml) at 0°C was added a solution of di-*tert*-butyl dicarbonate (36.7g) in dichloromethane (50ml) dropwise. Stirring was continued for 30 mins at this temperature and then stirred at RT for a further 24h. The reaction mixture was washed with 10%

aqueous citric acid (3 x 50ml), saturated aqueous sodium hydrogen carbonate solution (3 x 50ml), water (3 x 50ml) and brine (50ml). The organic layer was then dried (Na_2SO_4), filtered and the solvent removed under reduced pressure to give the title compound (33.9g, 87%) as a brown solid.

- 5 R_f 0.13 (1:1 diethyl ether/ hexane);
MS 278 (M^+).

Intermediate 2 4-(4-Difluoromethoxyphenyl)piperazine-1-carboxylic acid *tert*-butyl ester

- To a stirred solution of Intermediate 1 (2.0g) in 1,4-dioxan (50ml) at 100 °C was
10 added a solution of sodium hydroxide (0.86g) in water (5ml). Through this mixture was bubbled chlorodifluoromethane for 15 mins at this temperature before being allowed to cool to RT. The solvent was removed under reduced pressure and resulting residue was partitioned between diethyl ether (100ml) and water (50ml). The organic layer collected and further washed with saturated aqueous sodium hydrogencarbonate solution (3 x
15 50ml), water (3 x 50ml) and brine (50ml). The organic layer was then dried (Na_2SO_4), filtered and the solvent removed under reduced pressure to give the title compound (1.44g, 61%) as a beige solid.

R_f 0.51 (1:1 diethyl ether/ hexane);
MS 329 (MH^+).

- 20 **Intermediate 3 1-(4-Difluoromethoxyphenyl)piperazine dihydrochloride**

- To a stirred solution of Intermediate 2 (1.4g) in dichloromethane (10ml) at 0 °C was added a solution of trifluoroacetic acid (5ml) in dichloromethane (5ml). Stirring was continued for 30 mins at this temperature and then stirred at RT for a further 2h. The solvent was removed under reduced pressure and the resulting residue azeotroped with
25 1:1 hexane/dichloromethane (3x 20ml). Treatment of this material with a solution of hydrogen chloride in diethyl ether (1.0M, 20ml) gave a suspension, which was subsequently collected by filtration. The precipitation was washed further with diethyl ether (3 x 20ml) and dried under reduced pressure to give the title compound (0.74g, 76%).

- 30 R_f 0.15 (ethyl acetate);
MS 229 (MH^+).

Intermediate 4 2-(Bromomethyl)benzoic acid methyl ester

Prepared as described by Dhanoa, *J.Med.Chem.*, **36**, 4230, (1993).

R_f 0.44 (5:1 hexane/diethyl ether);

MS 229 (M⁺).

5 Intermediate 5 2-(Cyanomethyl)benzenesulfonyl chloride

Prepared as described by Sianesi *et al*, *Chem. Ber.*, **103**, 1992-2002, (1970).

R_f 0.60 (1:1 hexane/ethyl acetate);

MS 216 (M⁺).

Intermediate 6 (3a,7a-Dihydrobenzofuran-2-ylmethyl)methylamine

10 To a stirred solution of benzofuran-2-carboxaldehyde (1.50g) and 4Å molecular sieves in dichloroethane (50ml) under an atmosphere of nitrogen was added methylamine in THF (2.0M, 10.3ml) and acetic acid (1.23g). Stirring was continued for 2h before sodium triacetoxyborohydride (2.18g) was added and stirring as continued overnight. The mixture was filtered, absorbed onto silica gel and chromatographed eluting with
15 dichloromethane/methanol (9:1) to yield the title compound (1.05g, 64%) as an off-white solid.

R_f 0.30 (9:1 dichloromethane/methanol);

MS 229 (M⁺).

20 Intermediate 7 2-[4-(4-Chlorophenyl)piperazine-1-sulfonyl]benzoic acid methyl ester

To stirred suspension of 4-(4-chlorophenyl)piperazine dihydrochloride (3.0g) in dichloromethane (100ml) at 0°C was added triethylamine (4.6ml). After 15mins, a solution of 2-chlorosulfonylbenzoic acid methyl ester (2.90g) in dichloromethane (30ml) was added. Stirring was continued overnight with the temperature rising to RT. The reaction
25 mixture was diluted with dichloromethane (100ml) and then washed with 10% aqueous citric acid (3 x 50ml), saturated aqueous sodium hydrogen carbonate solution (3 x 50ml), water (3 x 50ml) and brine (50ml). The organic layer was then dried (MgSO₄), filtered and the solvent removed under reduced pressure to give the title compound (0.24g, 48%) as an off-white solid.

30 R_f 0.57 (1:1 hexane/ethyl acetate);

MS 395 (MH⁺).

Similarly prepared were:-

Intermediate 8 2-[4-(4-Chlorophenoxy)piperidine-1-sulfonyl]benzoic acid methyl ester

From 2-chlorosulfonylbenzoic acid methyl ester (587mg) and 4-(4-chlorophenoxy)piperidine (577mg) as a brown oil (0.83g, 97%).

5 R_f 0.53 (1:1 diethyl ether/hexane);

MS 410.6 (MH^+).

Intermediate 9 2-[4-(4-Difluoromethoxyphenyl)piperazine-1-sulfonyl]benzoic acid methyl ester

From 2-chlorosulfonylbenzoic acid methyl ester (587mg) and Intermediate 3
10 (602mg) as a brown oil, (0.85g, 99%).

R_f 0.44 (1:1 diethyl ether/hexane);

MS 426 (M^+).

Intermediate 10 2-[4-(3,5-Dichlorophenyl)piperazine-1-sulfonyl]benzoic acid methyl ester

15 From 2-chlorosulfonylbenzoic acid methyl ester (587mg) and 4-(3,5-dichlorophenyl)piperazine (462mg) as a green solid (0.76g, 89%).

R_f 0.58 (1:1 diethyl ether/hexane);

MS 429 (M^+).

Intermediate 11 2-[4-(4-Trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]benzoic acid methyl ester

20

From 2-chlorosulfonylbenzoic acid methyl ester (587mg) and 4-(4-trifluoromethylpyridin-2-yl)piperidine (462mg) as a brown oil (0.83g, 96%).

R_f 0.62 (ethyl acetate);

MS 429 (M^+).

25 **Intermediate 12** 2-[4-(4-Chlorobenzoyl)piperidine-1-sulfonyl]benzoic acid methyl ester

From 2-chlorosulfonylbenzoic acid methyl ester (0.25g) and 4-(4-chlorobenzoyl)piperidine (221mg) as a yellow oil (0.28g, 78%).

R_f 0.55 (1:1 diethyl ether/hexane);

30 MS 422.6 (MH^+).

Intermediate 13 2-(4-Benzylpiperidine-1-sulfonyl)benzoic acid methyl ester

From 2-chlorosulfonylbenzoic acid methyl ester (587mg) and 4-benzyl-piperidine (350mg) as a brown oil (652mg, 87%).

R_f 0.35 (1:1 diethyl ether/hexane);

MS 373 (M⁺).

Intermediate 14 2-[(4-Methoxyphenyl)-methyl-sulfamoyl]benzoic acid methyl ester

5 From 2-chlorosulfonylbenzoic acid methyl ester (587mg) and *N*-(4-methoxyphenyl)-methylamine (0.27g) as a brown oil (0.53g, 79%).

R_f 0.3 (1:1 diethyl ether/hexane);

MS 335 (M⁺).

Intermediate 15 2-[4-(Pyridin-2-yl)piperazine-1-sulfonyl]benzoic acid methyl ester

10

 From 2-chlorosulfonylbenzoic acid methyl ester (469mg) and 1-pyridin-2-yl-piperazine (408mg) as a yellow oil (0.63g, 87%).

R_f 0.35 (1:1 diethyl ether/hexane);

MS 361 (M⁺).

Intermediate 16 2-(3,4-Dihydro-1*H*-isoquinoline-2-sulfonyl)benzoic acid methyl ester

15

 From 2-chlorosulfonylbenzoic acid methyl ester (469mg) and 1,2,3,4-tetrahydro-isoquinoline (333mg) as a yellow oil (475mg, 71%).

R_f 0.25 (1:1 diethyl ether/hexane);

20 MS 331 (M⁺)

Intermediate 17 2-(Acetylsulfanylmethyl)benzoic acid methyl ester

 To a stirred solution of Intermediate 4 (2.92g) in DMF (5ml) at 0°C was added potassium thioacetate (1.60g). Stirring was continued for 30 mins at this temperature and then stirred at RT for a further 1h. The mixture was poured into ice/water (100ml) and extracted with diethyl ether (3 x 50ml). The resulting ethereal extracted was further
25 washed with saturated aqueous sodium hydrogen carbonate solution (50ml), water (50ml) and brine (50ml). The organic layer was then dried (Na₂SO₄), filtered and the solvent removed under reduced pressure to give a brown oil. Purification by silica gel column chromatography, eluting with 5:1 hexane/diethyl ether gave the title compound
30 (2.05g, 75%) as a colourless oil which subsequently solidified.

R_f 0.25 (5:1 hexane/diethyl ether);

MS 247 ([M+Na]⁺).

Intermediate 18 2-(Chlorosulfonylmethyl)benzoic acid methyl ester

To a stirred solution of Intermediate 17 (2g) in glacial acetic acid (1ml) at 5 °C was added water (100ml). Through this suspension was bubbled chlorine gas for 20 minutes until a finely divided green suspension developed. Addition of gas was stopped and stirring continued for 30 mins before dichloromethane (150ml) was added. The organic was then collected and washed with saturated aqueous sodium hydrogen carbonate solution (50ml), water (50ml) and brine (50ml). The resulting extracts were dried (Na₂SO₄) and the solvent removed under reduced pressure to give the title compound (0.95g, 85 %) as a white solid.

10 R_f 0.48 (5:1 hexane/diethyl ether).

Intermediate 19 2-[4-(4-Chlorophenyl)piperazine-1-sulfonylmethyl]benzoic acid methyl ester

To stirred suspension of 4-(4-chlorophenyl)piperazine dihydrochloride (1.1g) in dichloromethane (10ml) at 0°C was added triethylamine (2ml). After 15mins, a solution of Intermediate 18 (0.49g) in dichloromethane (5ml) was added. Stirring was continued at this temperature for 30 mins and then at RT for 1hr. The reaction mixture was diluted with dichloromethane (100ml) and then washed with aqueous 10% citric acid (3 x 50ml), saturated aqueous sodium hydrogen carbonate solution (3 x 50ml), water (3 x 50ml) and brine (50ml). The organic layer was then dried (Na₂SO₄), filtered and the solvent removed under reduced pressure to give the title compound (0.24g, 48%) as a yellow oil.

R_f 0.55 (1:1 hexane/diethyl ether);

MS 409.5 (MH⁺).

Similarly prepared were:-

25 **Intermediate 20 2-[4-(4-Chlorophenoxy)piperidine-1-sulfonylmethyl]benzoic acid methyl ester**

From Intermediate 18 (621mg) and 4-(4-chlorophenoxy)piperidine (524mg) as a yellow oil (0.16g, 18%).

R_f 0.36 (1:1 diethyl ether/hexane);

30 MS 423.5 (MH⁺).

Intermediate 21 2-[4-(4-Chlorobenzoyl)piperidine-1-sulfonylmethyl]benzoic acid methyl ester

From Intermediate 18 (621mg) and 4-(4-chlorobenzoyl)piperidine (520mg) as a yellow oil (0.05g, 6%).

5 R_f 0.39 (1:1 diethyl ether/hexane).

Intermediate 22 2-(3,4-Dihydro-1-*H*-isoquinoline-2-sulfonylmethyl)benzoic acid methyl ester

From Intermediate 18 (621mg) and 3,4-dihydro-1-*H*-isoquinoline (266mg) as a colourless oil (0.05g, 7%).

10 R_f 0.38 (1:1 diethyl ether/hexane);

MS 346 (MH^+).

Intermediate 23 2-[(Benzofuran-2-ylmethyl-methyl-sulfamoyl)methyl]benzoic acid methyl ester

15 From Intermediate 18 (0.45g) and Intermediate 6 (0.30g) as a yellow oil (0.23g, 34%).

R_f 0.16 (1:1 diethyl ether/hexane);

MS 373 (M^+).

Intermediate 24 2-[4-(Pyridin-2-yl)piperazine-1-sulfonylmethyl]benzoic acid methyl ester

20 From Intermediate 18 (0.50g) and 1-(pyridin-2-yl)piperazine (408mg) as a beige solid (628mg, 66%).

R_f 0.21 (1:1 diethyl ether/hexane);

MS 375 (M^+).

Intermediate 25 2-[4-[5-(Trifluoromethyl)pyridin-2-yl]piperazine-1-sulfonylmethyl]benzoic acid methyl ester

25 From Intermediate 18 (0.50g) and (5-trifluoromethylpyridin-2-yl) piperazine as a beige solid (712mg, 65%).

R_f 0.13 (1:1 diethyl ether/hexane);

MS 443 (M^+).

Intermediate 26 2-{4-[4-(1,1-Difluoromethoxy)phenyl]piperazine-1-sulfonylmethyl}benzoic acid methyl ester

30 From Intermediate 18 (0.3g) and Intermediate 3 (0.451g) as a beige solid (369mg, 79%).

R_f 0.5 (diethyl ether);

MS 440 (M⁺).

Intermediate 27 **2-{[(4-Methoxyphenyl)methylsulfamoyl]methyl}benzoic acid methyl ester**

5 From Intermediate 18 (0.5g) and 4-methoxyphenyl-N-methylamine (278mg) as a brown oil (479mg, 62%).

R_f 0.57 (1:1 diethyl ether/hexane);

MS 350 (M⁺).

Intermediate 28 **{ 2 - [4 - (4 - C h l o r o p h e n y l) p i p e r a z i n e - 1 - sulfonyl]phenyl}acetonitrile**

10 To stirred suspension of 4-(4-chlorophenyl)piperazine dihydrochloride (400mg) in dichloromethane (25ml) at RT was added triethylamine (0.78ml). After 15mins, a solution of Intermediate 5 (500mg) in dichloromethane (5ml) was added. Stirring was continued for 2h. The reaction mixture was diluted with dichloromethane (50ml) and
15 then washed with aqueous citric acid (10%, 2 x 20ml), saturated aqueous sodium hydrogen carbonate solution (2 x 20ml), water (2 x 20ml) and brine (20ml). The organic layer was then dried (MgSO₄), filtered and the solvent removed under reduced pressure. The residue was chromatographed (2:1 hexane/ethyl acetate) to give the title compound (0.43g, 61%) as an off-white solid.

20 R_f 0.37 (2:1 hexane/ethyl acetate).

Similarly prepared were:-

Intermediate 29 **2-Cyanomethyl-N-(4-methoxyphenyl)-N-methyl-benzenesulfonamide**

25 From Intermediate 5 (431mg) and N-(4-methoxyphenyl)methylamine (274mg) as an off-white solid (235mg, 37%).

R_f 0.23 (2:1 hexane/ethyl acetate);

MS 317(MH⁺).

Intermediate 30 **{ 2 - [4 - (4 - D i f l u o r o m e t h o x y p h e n y l) p i p e r a z i n e - 1 - sulfonyl]phenyl}-acetonitrile**

30 From Intermediate 3 (431mg) and 1-(4-difluoromethoxyphenyl)piperazine (456mg) as a white solid (540mg, 66%).

R_f 0.24 (2:1 hexane/ethyl acetate);

MS 407(MH⁺).

Intermediate 31 {2-[4-(5-Trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]phenyl}acetonitrile

From Intermediate 11 (433mg) and 1-[5-(trifluoromethyl)pyrid-2-yl]piperazine (462mg) as a white solid (683mg, 83%).

5 R_f 0.37 (2:1 hexane/ethyl acetate);

MS 410 (MH^+).

Intermediate 32 2-{2-[4-(4-Chlorophenyl)piperazine-1-sulfonyl]phenyl}-3-methyl-butyronitrile

Sodium hydride (43mg of a 60% dispersion in oil) was added to a solution of
10 Intermediate 28 (400mg) in THF (20ml). After stirring for 5 min, isopropyl iodide (271mg) was added. The mixture was stirred at room temperature for 5 min and then at reflux for 30 min. It was cooled to room temperature and diluted with water (30ml) before being extracted with ethyl acetate (3 x 30ml). The combined extracts were washed with water (2 x 20ml) and brine (20ml), then dried ($MgSO_4$), evaporated and
15 chromatographed (4:1 hexane/ethyl acetate) to give the title compound (235mg, 53%) as a white foam.

R_f 0.42 (3:1 hexane: diethyl ether);

MS 417 (MH^+).

Example 1 2-[4-(4-Chlorophenyl)piperazine-1-sulfonyl]benzoic acid

20 To a stirred solution of Intermediate 7 (2.00g) in a mixture of methanol (50ml) and THF (30ml) was added a solution of lithium hydroxide monohydrate (1.06g) in water (20ml). The resulting suspension was heated to reflux for 2h. On cooling the solvent was removed under reduced pressure and the resulting residue partitioned between diethyl ether (50ml) and water (100ml). The aqueous layer was collected and
25 acidified to pH 5 with citric acid. The aqueous mixture was then extracted with ethyl acetate (4 x 50ml) and the combined organic layers washed with water (40ml) and brine (40ml). Following drying (Na_2SO_4), the solvent was removed under reduced pressure to give the title compound (1.48mg, 77%) as an off-white solid.

R_f 0.12 (1:1 hexane: diethyl ether);

30 MS 381 (MH^+).

Similarly prepared were:-

Example 2 2-[4-(4-Chlorophenoxy)piperidine-1-sulfonyl]benzoic acid

From Intermediate 8 (830mg) as a white foam (0.53g, 66%).

R_f 0.58 (10% methanol/dichloromethane);

MS 396.5 (MH⁺).

Example 3 2-[4-(4-Difluoromethoxyphenyl)piperazine-1-sulfonyl]benzoic acid

5 From Intermediate 9 (850mg) as a beige solid (0.53g, 80%).

R_f 0.35 (10% methanol/dichloromethane);

MS 412 (M⁺).

Example 4 2-[4-(3,5-Dichlorophenyl)piperazine-1-sulfonyl]benzoic acid

From Intermediate 10 (760mg) as a yellow solid (0.55g, 75%).

10 R_f 0.52 (10% methanol/dichloromethane);

MS 415 (M⁺).

Example 5 2-[4-(4-Trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]benzoic acid

From Intermediate 11 (830mg) as a white foam (0.58g, 93%).

15 R_f 0.58 (10% methanol/dichloromethane);

MS 416 (MH⁺).

Example 6 2-[4-(4-Chlorobenzoyl)piperidine-1-sulfonyl]benzoic acid

From Intermediate 12 (266mg) as a white foam (0.18g, 70%).

R_f 0.46 (10% methanol/dichloromethane);

20 MS 408.5 (MH⁺).

Example 7 2-(4-Benzylpiperidine-1-sulfonyl)benzoic acid

From Intermediate 13 (652mg) as a cream solid (430mg, 68%).

R_f 0.35 (10% methanol/dichloromethane);

MS 359 (M⁺).

25 **Example 8 2-[(4-Methoxyphenyl)methylsulfamoyl]benzoic acid**

From Intermediate 14 (242mg) as a beige solid (148mg, 64%).

R_f 0.1 (5% methanol/dichloromethane);

MS 321 (M⁺).

Example 9 2-[(4-(Pyridin-2-yl)piperazine-1-sulfonyl]benzoic acid

30 From Intermediate 15 (630mg) as a white solid (200mg, 35%).

R_f 0.20 (10% methanol/dichloromethane);

MS 347 (M⁺).

Example 10 **2-(3,4-Dihydro-1*H*-isoquinoline-2-sulfonyl)benzoic acid**

From Intermediate 16 (475mg) as a white solid (368mg, 81%).

R_f 0.3 (5% methanol/dichloromethane);

MS 317 (M⁺).

5 **Example 11** ***N*-Hydroxy-2-[4-(4-Chlorophenyl)piperazine-1-sulfonyl]benzamide**

To a stirred solution of Example 1 (1.00g) and oxalyl chloride (1.15ml) in dichloromethane (30ml) at RT was added DMF (1 drop). Stirring was continued at this temperature for 1h before the solvent was removed under reduced pressure. The residue
10 was azeotroped with 1:1 hexane/dichloromethane (3x 60ml) and then dispersed in THF. The suspension was cooled to 0°C and treated with a solution of hydroxylamine (0.8ml, 50%w/w). The reaction was stirred for 1h at RT and then the solvent was removed under reduced pressure. The residue was treated with water (30ml) and stirred for 1.5h. The solid was collected and dried to give the title compound (1.00g, 96%) as a white solid.

15 R_f 0.56 (ethyl acetate);

MS 410.7 (MH⁺).

Similarly prepared were:-

Example 12 ***N*-Hydroxy-2-[4-(4-Chlorophenoxy)piperidine-1-sulfonyl]benzamide**

20 From Example 2 (0.54g) as a beige foam (0.3g, 54%).

R_f 0.48 (10% methanol/dichloromethane);

MS 411 (MH⁺).

Example 13 ***N*-Hydroxy-2-[4-(4-Difluoromethoxyphenyl)piperazine-1-sulfonyl]benzamide**

25 From Example 3 (0.65g) as a beige foam (0.28g, 41%).

R_f 0.42 (10% methanol/dichloromethane);

MS 427 (M⁺).

Example 14 ***N*-Hydroxy-2-[4-(3,5-Dichlorophenyl)piperazine-1-sulfonyl]benzamide**

30 From Example 4 (0.55g) as a beige solid (0.29g, 52%).

R_f 0.51 (10% methanol/dichloromethane);

MS 430 (M⁺).

Example 15 *N*-Hydroxy-2-[4-(4-Trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]benzamide

From Example 5 (0.75g) as a pale yellow solid (0.29g, 37%).

R_f 0.6 (10%methanol/dichloromethane);

5 MS 430 (M⁺).

Example 16 *N*-Hydroxy-2-[4-(4-Chlorobenzoyl)piperidine-1-sulfonyl]benzamide

From Example 6 (460mg) as a white foam (0.12g, 25%).

R_f 0.25 (5%methanol/dichloromethane);

10 MS 423.5 (MH⁺).

Example 17 *N*-Hydroxy-2-(4-Benzylpiperidine-1-sulfonyl)benzamide

From Example 7 (400mg) as a beige solid (56mg, 13%).

R_f 0.45 (10%methanol/dichloromethane);

MS 375.5 (MH⁺).

15 **Example 18** *N*-Hydroxy-2-[(4-methoxyphenyl)methylsulfamoyl]benzamide

From Example 8 (145mg) as a beige solid (33mg, 20%).

R_f 0.25 (5%methanol/dichloromethane);

MS 337 (MH⁺).

Example 19 *N*-Hydroxy-2-[4-(pyridin-2-yl)piperazine-1-sulfonyl]benzamide

20

From Example 9 (200mg) as a white solid (43mg, 21%).

R_f 0.42 (10%methanol/dichloromethane).

Example 20 2-(3,4-Dihydro-1*H*-isoquinoline-2-sulfonyl)-*N*-hydroxybenzamide

25 From Example 10 (365mg) as a white solid (59mg, 15%).

R_f 0.44 (10%methanol/dichloromethane);

MS 332 (M⁺).

Example 21 2-[4-(4-Chlorophenyl)piperazine-1-sulfonylmethyl]benzoic acid

30

To a stirred solution of Intermediate 19 (0.25g) in 1:1:1 methanol/THF/water (30ml) was added lithium hydroxide monohydrate (0.5g). The resulting suspension was heated to reflux for 2.5h. On cooling the solvent was removed under reduced pressure and the resulting residue partitioned between diethyl ether (50ml) and water (20ml). The

aqueous layer was collected and acidified to pH 5 with citric acid. The aqueous mixture was then extracted with ethyl acetate (3x 50ml) and the combined organic layers washed with water (10ml) and brine (10ml). Following drying (Na₂SO₄), the solvent was removed under reduced pressure to give a pale brown oil. The material was dissolved in a minimum volume of ethyl acetate and treated with excess hexane to give a precipitate. Filtration and washing with diethyl ether (3x 5ml) gave the title compound (113mg, 46%) as a white solid.

R_f 0.62 (10% methanol/dichloromethane);

MS 395.5 (MH⁺).

Similarly prepared were:-

Example 22 **2-[4-(4-Chlorophenoxy)piperidine-1-sulfonylmethyl]benzoic acid**

From Intermediate 20 (300mg) as a white solid (240mg, 44%).

R_f 0.35 (10% methanol/dichloromethane).

Example 23 **2-[4-(4-Chlorobenzoyl)piperidine-1-sulfonylmethyl]benzoic acid**

From Intermediate 21 (400mg) as a white solid (350mg, 90%).

R_f 0.30 (10% methanol/dichloromethane);

MS 422 (MH⁺).

Example 24 **2-(3,4-Dihydro-1H-isoquinoline-2-sulfonylmethyl)benzoic acid**

From Intermediate 22 (400mg) as a white solid (261mg, 68%).

R_f 0.10 (5% methanol/dichloromethane);

MS 332 (MH⁺).

Example 25 **2-[(Benzofuran-2-ylmethyl-methyl-sulfamoyl)methyl]benzoic acid**

From Intermediate 23 (232mg) as a white solid (57mg, 25%).

R_f 0.15 (5% methanol/dichloromethane);

MS 358 (MH⁺).

Example 26 **2-[4-(Pyridin-2-yl)piperazine-1-sulfonylmethyl]benzoic acid**

From Intermediate 24 (686mg) as a white solid (104mg, 15%).

R_f 0.21 (5% methanol/dichloromethane);

MS 362 (MH⁺).

Example 27 **2-[4-(5-Trifluoromethylpyridin-2-yl)piperazine-1-sulfonylmethyl]benzoic acid**

From Intermediate 25 (712mg) as a white solid (110mg, 16%).

R_f 0.26 (10% methanol/dichloromethane);

5 MS 430 (MH⁺).

Example 28 **2-[4-[4-(1,1-Difluoromethoxy)phenyl]piperazine-1-sulfonylmethyl]benzoic acid**

From Intermediate 26 (367mg) as a pink solid (176mg, 49%).

R_f 0.30 (10% methanol/dichloromethane);

10 MS 427 (MH⁺).

Example 29 **2-([(4-Methoxyphenyl)methyl-sulfamoyl]methyl)benzoic acid**

From Intermediate 27 (429mg) as a white solid (309mg, 75%).

R_f 0.30 (10% methanol/dichloromethane);

MS 334 (MH⁺).

15 **Example 30** **2-[4-(4-Chlorophenyl)piperazine-1-sulfonylmethyl]-N-hydroxybenzamide**

To a stirred solution of Example 21 (0.16g) and oxalyl chloride (1ml) in dichloromethane (10ml) at RT was added DMF, with evolution of gas. Stirring was continued at this temperature for 2h before the solvent was removed under reduced pressure. The residue was azeotroped with 1:1 hexane/dichloromethane (3 x 20ml) and then dispersed in THF. The suspension was cooled to 0°C and treated with a 50% by weight solution of hydroxylamine in water (1ml). The reaction was stirred for 1h at RT and then the solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (50ml) and water (20ml). Collection of the organic layer was followed by washing of this layer with saturated aqueous sodium hydrogen carbonate solution (10ml), water (5ml) and brine (10ml). The resulting extracts were dried (Na₂SO₄) and the solvent removed under reduced pressure to give a pale brown oil. This material was dissolved in a minimum volume of ethyl acetate and then treated with excess hexane to give a precipitate. The solid was collected by filtration, washing with diethyl ether (3x 10ml) to give the title compound (0.02g, 14%) as a beige solid.

R_f 0.62 (10%methanol/dichloromethane);

MS 410.7 (MH⁺).

Similarly prepared were:-

Example 31 **2-[4-(4-Chlorophenoxy)piperidine-1-sulphonylmethyl]-N-hydroxybenzamide**

From Example 22 (240mg) as a white solid (25mg, 10%).

R_f 0.25 (5% methanol/dichloromethane);

5 MS 425.6 (MH⁺).

Example 32 **2-[4-(4-Chlorobenzoyl)piperidine-1-sulfonylmethyl]-N-hydroxybenzamide**

From Example 23 (370mg) as a beige solid (15mg, 4%).

R_f 0.3 (5% methanol/dichloromethane);

10 MS 437.5 (MH⁺).

Example 33 **2-(3,4-Dihydro-1H-isoquinoline-2-sulfonylmethyl)-N-hydroxybenzamide**

From Example 24 (261mg) as a white solid (75mg, 30%).

R_f 0.21 (5% methanol/dichloromethane);

15 MS 347 (MH⁺).

Example 34 **2-[(Benzofuran-2-ylmethyl-methyl-sulfamoyl)methyl]-N-hydroxybenzamide**

From Example 25 (50mg) as a white solid (22mg, 44%).

R_f 0.21 (5% methanol/dichloromethane);

20 MS 375 (MH⁺).

Example 35 **N-Hydroxy-2-[4-(5-trifluoromethylpyridin-2-yl)piperazine-1-sulfonylmethyl]benzamide**

From Example 27 (100mg) as a white solid (42mg, 40%).

R_f 0.16 (5% methanol/dichloromethane);

25 MS 443 (MH).

Example 36 **2-{4-[4-(1,1-Difluoromethoxy)phenyl]piperazine-1-sulphonylmethyl}-N-hydroxybenzamide**

From Example 28 (166mg) as a white solid (93mg, 54%).

R_f 0.23 (5% methanol/dichloromethane);

30 MS 440 (MH).

Example 37 **N-Hydroxy-2-{[(4-methoxyphenyl)methyl-sulfamoyl]methyl}benzamide**

From Example 29 (289mg) as a white solid (138mg, 45%).

R_f 0.28 (10% methanol/dichloromethane);

MS 349 (MH⁺).

Example 38 {2-[4-(4-Chlorophenyl)piperazine-1-sulfonyl]phenyl}acetic acid

5 A mixture of Intermediate 22 (417mg) and 1M sodium hydroxide solution (30ml) was refluxed for 72 hours. The mixture was cooled and acidified to pH1 with 6M hydrochloric acid. The mixture was extracted with ethyl acetate (4 x 20ml) and the combined extracts were washed with water (2 x 20ml), brine (20ml) and dried (MgSO₄). The mixture was filtered and evaporated to dryness to give the title compound as a pale
10 yellow solid (360mg, 82%).

R_f 0.23 (1:1 ethyl acetate/hexane);

MS 395 (MH⁺).

Similarly prepared were:-

Example 39 {2-[(4-Methoxyphenyl)methyl-sulfamoyl]phenyl}acetic acid

15 From Intermediate 23 (230mg) as a white solid (242mg, 99%).

R_f 0.35 (2:1 ethyl acetate/hexane);

MS 336 (MH⁺).

Example 40 {2-[4-(4-Difluoromethoxyphenyl)piperazine-1-sulfonyl]phenyl}acetic acid

20 From Intermediate 30 (530mg) as a brown oil (145mg, 26%).

R_f 0.10 (2:1 ethyl acetate/hexane);

MS 426 (MH⁺).

Example 41 {2-[4-(5-Trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]phenyl}acetic acid

25 From Intermediate 31 (660mg) as an off white solid (609mg, 85%).

R_f 0.25 (10:1 dichloromethane/methanol);

MS 430 (MH⁺).

Example 42 {4,5-Dimethoxy-2-[4-(5-trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]phenyl}acetic acid

30 {4,5-Dimethoxy-2-[4-(5-trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]-phenyl}acetic acid methyl ester (0.3g) was taken up in methanol (10ml), tetrahydrofuran (10ml) and water (10ml). Lithium hydroxide (125mg) was added and the reaction stirred at RT for 16 hrs. The reaction was diluted with water (10ml), its volume reduced to one

third *in vacuo*, and the reaction extracted with diethyl ether (3 x 15ml). The aqueous layer was acidified to pH 4 with 2M hydrochloric acid and extracted with ethyl acetate (4 x 25ml). The combined ethyl acetate extracts were washed with water (25ml) and brine (25ml) and dried over sodium sulphate. The solvent was removed *in vacuo* to yield the title compound as a white solid (291mg, 100%).

R_f 0.19 (2:1 ethyl acetate/hexane);

MS 490(MH⁺).

Example 43 2-{2-[4-(4-Chlorophenyl)piperazine-1-sulfonyl]phenyl}-3-methylbutyric acid

Intermediate 32 (0.23g) was taken up in ethylene glycol (25ml) with potassium hydroxide (155mg) and heated at 150°C for 72 hrs. After cooling the reaction was diluted with water (50ml), and extracted with diethyl ether (3 x 15ml). The aqueous layer was acidified to pH 1 with 2M hydrochloric acid, and extracted with ethyl acetate (4 x 25ml). The combined ethyl acetate extracts were washed with water (2 x 25ml), brine (25ml) and dried over magnesium sulphate. The solvent was removed *in vacuo* to yield a brown oil which was purified by flash chromatography (eluent 2:1 hexane/ethyl acetate) to yield the title compound as a white solid (152mg, 63%).

R_f 0.18 (1:2 ethyl acetate/hexane);

MS 437(MH⁺).

Example 44 [2-(Benzofuran-2-ylmethyl-methyl-sulfamoyl)phenyl]acetic acid

To stirred suspension of Intermediate 6 (322mg) in dichloromethane (20ml) at RT was added triethylamine (0.84ml). After 15min, a solution of Intermediate 5 (431mg) in dichloromethane (5ml) was added. Stirring was continued for 1h before the solvent was removed *in vacuo*. The residue was treated with sodium hydroxide solution (3M, 20ml) and refluxed for 24h. The mixture was cooled, washed with diethyl ether (20ml) and acidified to pH3 with 2M hydrochloric acid and extracted with ethyl acetate (4 x 20 ml). The combined ethyl acetate layers were washed with water (20ml), brine (20ml) and dried over magnesium sulphate. Filtration and evaporation of the solvent yielded the title compound as an off-white solid (159mg, 22%).

R_f 0.30 (2:1 ethyl acetate/hexane);

MS 360 (MH⁺).

Similarly prepared were:-

Example 45 **[2-[4-(Pyridin-2-yl)piperazine-1-sulfonyl]phenyl]acetic acid**

From Intermediate 5 (431mg) and 4-(2-pyridinyl)piperazine (326mg) as an off-white solid (335mg, 46%).

R_f 0.05 (2:1 ethyl acetate/hexane);

5 MS 362 (MH⁺).

Example 46 **{2-[4-(3,5-Dichlorophenyl)piperazine-1-sulfonyl]phenyl}acetic acid**

From Intermediate 5 (431mg) and 4-(3,5-dichlorophenyl)piperazine (462mg) as an off-white solid (265mg, 31%).

10 R_f 0.43 (2:1 ethyl acetate/hexane);

MS 430 (MH⁺).

Example 47 **{2-[4-(4-Chlorophenoxy)piperidine-1-sulfonyl]phenyl}acetic acid**

From Intermediate 5 (431mg) and 4-(4-chlorophenoxy)piperidine (496mg) as an off-white solid (206mg, 25%).

R_f 0.33 (2:1 ethyl acetate/hexane);

MS 410 (MH⁺).

Example 48 **[2-(4-Chlorobenzoyl)piperidine-1-sulfonyl]phenyl]acetic acid**

From Intermediate 5 (431mg) and 4-(4-chlorobenzoyl)piperidine (520mg) as an off-white solid (377mg, 45%).

R_f 0.26 (2:1 ethyl acetate/hexane);

MS 422 (MH⁺).

Example 49 **[2-(3,4-Dihydro-1*H*-isoquinoline-2-sulfonyl)phenyl]acetic acid**

From Intermediate 5 (431mg) and 3,4-dihydro-1*H*-isoquinoline (266mg) as an off-white solid (416mg, 63%).

R_f 0.38 (2:1 ethyl acetate/hexane);

MS 332 (MH⁺).

Example 50 **{2-[4-(4-Chlorophenyl)piperazine-1-sulfonyl]phenyl}-*N*-hydroxyacetamide**

30 To a stirred solution of Example 38 (0.35g) and oxalyl chloride (2ml) in dichloromethane (20ml) at RT was added DMF, with evolution of gas. Stirring was continued at this temperature for 2h before the solvent was removed under reduced pressure. The residue was azeotroped with 1:1 hexane/dichloromethane (3 x 20ml) and

then dispersed in THF. The suspension was cooled to 0°C and treated with a 50% by weight solution of hydroxylamine in water (1ml). The reaction was stirred for 1 hour at RT and then the solvent was removed under reduced pressure. The residue partitioned between ethyl acetate (50ml) and water (20ml). Collection of the organic layer was followed by washing of this layer with saturated aqueous sodium hydrogen carbonate solution (10ml), water (5ml) and brine (10ml). The resulting extracts were dried over sodium sulphate and the solvent removed under reduced pressure to give a pale brown oil. This material was dissolved in a minimum volume of ethyl acetate and then treated with excess hexane to give a precipitate. The solid was collected by filtration, washing with diethyl ether (3x 10ml) to give the title compound (238mg, 66%) as an off-white solid. R_f 0.42 (5:1 ethyl acetate/hexane); MS 410 (MH⁺).

Similarly prepared were:-

Example 51 **{2-[(4-Methoxyphenyl)methyl-sulfamoyl]phenyl}-N-hydroxyacetamide**

From Example 39 (229mg) as an off-white solid (218mg, 91%).

R_f 0.36 (10:1 dichloromethane/methanol);

MS 351 (MH⁺).

Example 52 **2-{2-[4-(4-Difluoromethoxyphenyl)piperazine-1-sulfonyl]phenyl}-N-hydroxyacetamide**

From Example 40 (135mg) as a brown solid (86mg, 61%).

R_f 0.38 (10:1 dichloromethane/methanol);

MS 441 (MH⁺).

Example 53 **N-Hydroxy-2-{2-[4-(5-trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]phenyl}acetamide**

From Example 41 (135mg) as an off-white solid (503mg, 82%).

R_f 0.42 (10:1 dichloromethane/methanol);

MS 444 (MH⁺).

Example 54 **2-{4,5-Dimethoxy-2-[4-(5-trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]phenyl}-N-hydroxyacetamide**

From Example 42 (260mg) as a white solid (237mg, 88%).

R_f 0.29 (10:1 dichloromethane/methanol);

MS 504 (MH⁺).

Example 55 2-{2-[4-(4-Chlorophenyl)piperazine-1-sulfonyl]phenyl}-*N*-hydroxy-3-methylbutyramide

From Example 43 (115mg) as a white solid (113mg, 95%).

R_f 0.37 (10:1 dichloromethane/methanol);

5 MS 451 (MH^+).

Example 56 [2-(Benzofuran-2-ylmethyl-methyl-sulfamoyl)phenyl]-*N*-hydroxyacetamide

From Example 44 (155mg) as an off-white solid (106mg, 66%).

R_f 0.37 (10:1 dichloromethane/methanol);

10 MS 375 (MH^+).

Example 57 [2-[(4-Pyridin-2-yl)piperazine-1-sulfonyl]phenyl]-*N*-hydroxyacetamide

From Example 45 (330mg) as an off-white solid (306mg, 86%).

R_f 0.27 (10:1 dichloromethane/methanol);

15 MS 389 (MH^+).

Example 58 2-{2-[4-(3,5-Dichlorophenyl)piperazine-1-sulfonyl]phenyl}-*N*-hydroxyacetamide

From Example 46 (260mg) as an off-white solid (230mg, 86%).

R_f 0.36 (10:1 dichloromethane/methanol);

20 MS 445 (MH^+).

Example 59 {2-[4-(4-Chlorophenoxy)piperidine-1-sulfonyl]phenyl}-*N*-hydroxyacetamide

From Example 47 (201mg) as an off-white solid (94mg, 45%).

R_f 0.37 (10:1 dichloromethane/methanol);

25 MS 424 (MH^+).

Example 60 [2-(4-Chlorobenzoylpiperidine-1-sulfonyl)phenyl]-*N*-hydroxyacetamide

From Example 48 (372mg) as an off-white solid (290mg, 75%).

R_f 0.36 (10:1 dichloromethane/methanol);

30 MS 437 (MH^+).

Example 61 2-(2-{4-[(4-Chlorophenyl)hydroxyiminomethyl]piperidine-1-sulfonyl}phenyl)-*N*-hydroxyacetamide

From Example 48 (372mg) as an off-white solid (32mg, 8%).

R_f 0.40 (10:1 dichloromethane/methanol);

MS 451 (MH⁺).

Example 62 **[2-(3,4-Dihydro-1*H*-isoquinoline-2-sulfonyl)phenyl]-*N*-hydroxyacetamide**

5 From Example 49 (300mg) as an off-white solid (212mg, 74%).

R_f 0.37 (10:1 dichloromethane/methanol);

MS 346 (MH⁺).

Example 63 **3-[4-(4-Chlorophenyl)piperazine-1-sulfonyl]benzoic acid**

10 To a suspension of 1-(4-chlorophenyl)piperazine dihydrochloride (539mg) and 3-(chlorosulfonyl)benzoic acid (441mg) in dichloromethane (50ml) was added diisopropylethylamine (0.8ml). After stirring overnight at room temperature the reaction mixture was washed with 2N HCl (3 x 25 ml) and brine (25 ml), dried over MgSO₄, filtered and evaporated to give the title compound as white solid (290mg, 38%).

MS 381 (M⁺).

15 **Example 64** **3-[4-(4-Chlorophenyl)piperazine-1-sulfonyl]-*N*-hydroxybenzamide**

20 To a suspension of Example 63 (190mg) was added O-(*tert*-butyldimethylsilyl)-hydroxylamine (81mg) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (96mg). After stirring overnight at room temperature ethyl acetate (100mL) was added and the organic layer was washed with water (2 x 25ml), saturated NaHCO₃ (2 x 25ml) and water (25ml), dried over MgSO₄, filtered and evaporated. The colourless oil was dissolved in dichloromethane (20ml) and treated with 1.0 M HCl solution in ether (1.5ml). Filtration afforded the title compound as a white solid (100mg, 50%).

R_f 0.6 (10% methanol in dichloromethane);

25 MS 396 (M⁺).

CLAIMS

1. Use of a compound for the manufacture of a medicament for the treatment or prevention of a condition associated with matrix metalloproteinase, ADAM or ADAM-TS enzymes, a condition that is mediated by TNF α or a condition involving a membrane-shedding event that is mediated by a metalloproteinase, wherein the compound is of formula (I)



10 wherein

$n = 0$ or 1 ;

$m = 0$ or 1 ;

X is $S(O)_{1-2}$;

Y is OH or NHOH;

15 W is aryl or heteroaryl;

R^1 is H, OR^7 or a group (optionally substituted with R^3) selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, C_{1-6} alkyl-aryl, heteroaryl, C_{1-6} alkyl-heteroaryl, cycloalkyl, C_{1-6} alkyl-cycloalkyl, heterocycloalkyl and C_{1-6} alkyl-heterocycloalkyl; and

R^2 is H or C_{1-6} alkyl;

20 or CR^1R^2 is cycloalkyl or heterocycloalkyl optionally substituted with R^3 or a group (optionally substituted with R^3) selected from C_{1-6} alkyl, aryl, C_{1-6} alkyl-aryl, heteroaryl and C_{1-6} alkyl-heteroaryl;

R^3 is OR^7 , COR^7 , CO_2R^8 , $CON(R^7)_2$, $N(R^7)_2$, NR^7COR^7 , $NR^7CON(R^7)_2$, $NR^7CO_2R^8$, $NR^7SO_2R^8$, $S(O)_{0-2}R^8$, $SO_2N(R^7)_2$ or cycloimidyl (optionally substituted with R^4);

25 R^4 is C_{1-6} alkyl;

B is H or a group (optionally substituted with R^5 or R^6) selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, C_{1-6} alkyl-aryl, heteroaryl, C_{1-6} alkyl-heteroaryl, cycloalkyl, C_{1-6} alkyl-cycloalkyl, heterocycloalkyl, C_{1-6} alkyl-heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl; and each instance of B may be the same or different;

30 or B-N-B is heterocycloalkyl optionally substituted with R^5 , R^6 , $=O$ or $=NOR^5$;

R^5 is a group (optionally substituted with R^6) selected from C_{1-6} alkyl, aryl, C_{1-6} alkyl-aryl, heteroaryl, C_{1-6} alkyl-heteroaryl, cycloalkyl, C_{1-6} alkyl-cycloalkyl, heterocycloalkyl and C_{1-6} alkyl-heterocycloalkyl;

R^6 is a group selected from $N(R^7)_2$, NR^7COR^7 , $NR^7CON(R^7)_2$, $NR^7CO_2R^8$,
 5 $NR^7SO_2R^8$, OR^7 , COR^7 , CO_2R^4 , $CON(R^7)_2$, $S(O)_{0-2}R^8$ and $SO_2N(R^7)_2$;

R^7 is H or a group selected from C_{1-6} alkyl, aryl, C_{1-6} alkyl-aryl, heteroaryl, C_{1-6} alkyl-heteroaryl, cycloalkyl, C_{1-6} alkyl-cycloalkyl, heterocycloalkyl and C_{1-6} alkyl-heterocycloalkyl, wherein said group is optionally substituted with R^8 , COR^8 , $SO_{0-2}R^8$, CO_2R^8 , OR^8 , $CONR^4R^8$, NR^4R^8 or $SO_2NR^4R^8$ and for each case of $N(R^7)_2$ the R^7 groups
 10 are the same or different or $N(R^7)_2$ is heterocycloalkyl optionally substituted with R^8 , COR^8 , $S(O)_{0-2}R^8$, CO_2R^8 , OR^8 , $CONR^4R^8$, NR^4R^8 or $SO_2NR^4R^8$; and

R^8 is C_{1-6} alkyl, aryl, C_{1-6} alkyl-aryl, heteroaryl or C_{1-6} alkyl-heteroaryl;

or a salt, solvate, hydrate, N-oxide, protected amino, protected carboxy or protected hydroxamic acid derivative thereof.

- 15 2. Use according to claim 1, wherein X is SO_2 .
3. Use according to claim 1 or claim 2, wherein B-N-B is optionally substituted heterocycloalkyl.
4. A compound as defined in any of claims 1 to 3, for therapeutic use, wherein Y is OH, m and n are both zero, and BNB is optionally substituted heterocycloalkyl.
- 20 5. A compound as defined in any of claims 1 to 3, for therapeutic use, wherein Y is OH, with the proviso that m and n are not both zero.
6. A compound as defined in any of claims 1 to 3, independent of use, wherein Y is NHOH.
7. A compound of claim 5 or claim 6, wherein m = 1.
- 25 8. A compound of any of claims 5 to 7, wherein n = 1.
9. A compound of claim 5 or claim 6, wherein m = 1 and n = 1.
10. A compound of any of claims 5 to 9, wherein at least one B is substituted C_{1-6} alkyl-aryl.
11. A compound of any of claims 4 to 9, wherein B is H or a group (optionally substituted with R^5 or R^6) selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, heteroaryl, C_{1-6} alkyl-heteroaryl, cycloalkyl, C_{1-6} alkyl-cycloalkyl, heterocycloalkyl, C_{1-6} alkyl-heterocycloalkyl, cycloalkenyl and heterocycloalkenyl; and each instance of B may be the same or different.
- 30

12. A compound of claim 11, wherein B is H or a group (optionally substituted with R⁵ or R⁶) selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, heterocycloalkyl, C₁₋₆ alkyl-cycloalkyl, heterocycloalkyl, C₁₋₆ alkyl-heterocycloalkyl, cycloalkenyl and heterocycloalkenyl; and each instance of B may be the same or different.
- 5 13. A compound of any of claims 4 to 12, wherein neither B is H.
14. A compound of claim 13, wherein BNB is heterocycloalkyl substituted with a substituted C₁₋₆ alkyl-aryl group.
15. A compound of claim 13, wherein BNB is heterocycloalkyl substituted with NOR⁵, R⁶ or a group (optionally substituted with R⁶) selected from C₁₋₆ alkyl, aryl, heteroaryl, C₁₋₆ alkyl-heteroaryl, cycloalkyl, C₁₋₆ alkyl-cycloalkyl, heterocycloalkyl and C₁₋₆ alkyl-heterocycloalkyl.
- 10 16. A compound of claim 13, wherein BNB is heterocycloalkyl substituted with NOR⁵, R⁶ or a group (optionally substituted with R⁶) selected from C₁₋₆ alkyl, aryl, heteroaryl, cycloalkyl, C₁₋₆ alkyl-cycloalkyl, heterocycloalkyl and C₁₋₆ alkyl-heterocycloalkyl.
- 15 17. A compound of claim 13, wherein BNB is heterocycloalkyl substituted with NOR⁵, R⁶ or a group (optionally substituted with R⁶) selected from C₁₋₆ alkyl, cycloalkyl, C₁₋₆ alkyl-cycloalkyl, heterocycloalkyl and C₁₋₆ alkyl-heterocycloalkyl.
18. A compound as defined in claim 1, selected from
- 20 2-[4-(4-chlorophenyl)piperazine-1-sulfonyl]benzoic acid,
2-[4-(4-chlorophenoxy)piperidine-1-sulfonyl]benzoic acid,
2-[4-(4-difluoromethoxyphenyl)piperazine-1-sulfonyl]benzoic acid,
2-[4-(3,5-dichlorophenyl)piperazine-1-sulfonyl]benzoic acid,
2-[4-(4-trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]benzoic acid,
2-[4-(4-chlorobenzoyl)piperidine-1-sulfonyl]benzoic acid,
- 25 2-(4-benzylpiperidine-1-sulfonyl)benzoic acid,
N-hydroxy-2-[4-(4-chlorophenyl)piperazine-1-sulfonyl]benzamide,
N-hydroxy-2-[4-(4-chlorophenoxy)piperidine-1-sulfonyl]benzamide,
N-hydroxy-2-[4-(4-difluoromethoxyphenyl)piperazine-1-sulfonyl]benzamide,
N-hydroxy-2-[4-(3,5-dichlorophenyl)piperazine-1-sulfonyl]benzamide,
- 30 *N*-hydroxy-2-[4-(4-trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]benzamide,
N-hydroxy-2-[4-(4-chlorobenzoyl)piperidine-1-sulfonyl]benzamide,
N-hydroxy-2-(4-benzylpiperidine-1-sulfonyl)benzamide,
2-[4-(4-chlorophenyl)piperazine-1-sulfonylmethyl]benzoic acid,

- {2-[4-(4-chlorophenyl)piperazine-1-sulfonyl]phenyl}acetic acid,
 {2-[(4-methoxyphenyl)methyl-sulfamoyl]phenyl}acetic acid,
 [2-(benzofuran-2-yl-methyl-methyl-sulfamoyl)phenyl]acetic acid,
 [2-(4-pyridin-2-yl-piperazine-1-sulfonyl)phenyl]acetic acid,
 5 {2-[4-(3,5-dichlorophenyl)piperazine-1-sulfonyl]phenyl}acetic acid,
 {2-[4-(4-chlorophenoxy)piperidine-1-sulfonyl]phenyl}acetic acid,
 [2-(4-chlorobenzoylpiperidine-1-sulfonyl)phenyl]acetic acid,
 [2-(3,4-dihydro-1*H*-isoquinoline-2-sulfonyl)phenyl]acetic acid,
 2-[4-(4-chlorophenyl)piperazine-1-sulfonylmethyl]-*N*-hydroxybenzamide,
 10 {2-[4-(4-chlorophenyl)piperazine-1-sulfonyl]phenyl}-*N*-hydroxyacetamide,
 [2-(benzofuran-2-yl-methyl-methyl-sulfamoyl)phenyl]-*N*-hydroxyacetamide,
 [2-(4-pyridin-2-yl-piperazine-1-sulfonyl)phenyl]-*N*-hydroxyacetamide,
 2-{2-[4-(3,5-dichlorophenyl)piperazine-1-sulfonyl]phenyl}-*N*-hydroxyacetamide,
 {2-[4-(4-chlorophenoxy)piperidine-1-sulfonyl]phenyl}-*N*-hydroxyacetamide,
 15 [2-(4-benzoylpiperidine-1-sulfonyl)phenyl]-*N*-hydroxyacetamide,
 [2-(3,4-dihydro-1*H*-isoquinoline-2-sulfonyl)phenyl]-*N*-hydroxyacetamide, and
 {2-[(4-methoxyphenyl)methyl-sulfamoyl]phenyl}-*N*-hydroxyacetamide.
19. A compound as defined in claim 1, selected from
 2-[(4-methoxyphenyl)methylsulfamoyl]benzoic acid,
 20 2-[(4-(pyridin-2-yl)piperazine-1-sulfonyl]benzoic acid,
 2-(3,4-dihydro-1*H*-isoquinoline-2-sulfonyl)benzoic acid,
N-hydroxy-2-[(4-methoxyphenyl)methylsulfamoyl]benzamide,
N-hydroxy-2-[4-(pyridin-2-yl)piperazine-1-sulfonyl]benzamide,
 2-(3,4-dihydro-1*H*-isoquinoline-2-sulfonyl)-*N*-hydroxybenzamide,
 25 2-[4-(4-chlorophenoxy)piperidine-1-sulfonylmethyl]benzoic acid,
 2-[4-(4-chlorobenzoyl)piperidine-1-sulfonylmethyl]benzoic acid,
 2-(3,4-dihydro-1*H*-isoquinoline-2-sulfonylmethyl)benzoic acid,
 2-[(benzofuran-2-ylmethyl-methyl-sulfamoyl)methyl]benzoic acid,
 2-[4-(pyridin-2-yl)piperazine-1-sulfonylmethyl]benzoic acid,
 30 2-[4-(5-trifluoromethylpyridin-2-yl)piperazine-1-sulfonylmethyl]benzoic acid,
 2-[4-[4-(1,1-difluoromethoxy)phenyl]piperazine-1-sulfonylmethyl]benzoic acid,
 2-[(4-methoxyphenyl)methyl-sulfamoyl]methylbenzoic acid,
 2-[4-(4-chlorophenoxy)piperidine-1-sulphonylmethyl]-*N*-hydroxybenzamide,

- 2-[4-(4-chlorobenzoyl)piperidine-1-sulfonylmethyl]-*N*-hydroxybenzamide,
 2-(3,4-dihydro-1H-isoquinoline-2-sulfonylmethyl)-*N*-hydroxybenzamide,
 2-[(benzofuran-2-ylmethyl-methyl-sulfamoyl)methyl]-*N*-hydroxybenzamide,
N-Hydroxy-2-[4-(5-trifluoromethylpyridin-2-yl)piperazine-1-
 5 sulfonylmethyl]benzamide,
 2-{4-[4-(1,1-difluoromethoxy)phenyl]piperazine-1-sulphonylmethyl}-*N*-
 hydroxybenzamide,
N-hydroxy-2-{[(4-methoxyphenyl)methyl-sulfamoyl]methyl}benzamide,
 {2-[4-(5-trifluoromethylpyridin-2-yl)piperazine-1-sulfonyl]phenyl}acetic acid,
 10 {4,5-dimethoxy-2-[4-(5-trifluoromethylpyridin-2-yl)piperazine-1-
 sulfonyl]phenyl}acetic acid,
 2-{2-[4-(4-chlorophenyl)piperazine-1-sulfonyl]phenyl}-3-methylbutyric acid,
 2-{2-[4-(4-difluoromethoxyphenyl)piperazine-1-sulfonyl]phenyl}-*N*-
 hydroxyacetamide,
 15 *N*-hydroxy-2-{2-[4-(5-trifluoromethylpyridin-2-yl)piperazine-1-
 sulfonyl]phenyl}acetamide,
 2-{4,5-dimethoxy-2-[4-(5-trifluoromethylpyridin-2-yl)-piperazine-1-
 sulfonyl]phenyl}-*N*-hydroxyacetamide,
 2-{2-[4-(4-chlorophenyl)piperazine-1-sulfonyl]phenyl}-*N*-hydroxy-3-
 20 methylbutyramide,
 2-(2-{4-[(4-chlorophenyl)hydroxyiminomethyl]piperidine-1-sulfonyl}phenyl)-*N*-
 hydroxyacetamide,
 3-[4-(4-chlorophenyl)piperazine-1-sulfonyl]benzoic acid, and
 3-[4-(4-chlorophenyl)piperazine-1-sulfonyl]-*N*-hydroxybenzamide.
- 25 20. A pharmaceutical composition for use in therapy, comprising a compound of any
 of claims 4 to 19, and a pharmaceutically-acceptable diluent or carrier.
21. Use of a compound according to any of claims 4 to 19, for the manufacture of a
 medicament for the treatment or prevention of a condition associated with matrix
 metalloproteinase, ADAM or ADAM-TS enzymes, a condition that is mediated by TNF
 30 α or a condition involving a membrane-shedding event that is mediated by a
 metalloproteinase.
22. Use according to any of claims 1 to 3 and 21, wherein the condition is selected
 from cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal

disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia, anorexia, acute infection, HIV infection, shock states, graft versus host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-independent anti-thrombosis.

5 23. Use according to any of claims 1 to 3 and 21, wherein the condition is selected from tumour growth, angiogenesis, tumour invasion and spread, metastasis, malignant ascites and malignant pleural effusion.

24. Use according to any of claims 1 to 3 and 21, wherein the condition is selected from cerebral ischaemia, ischaemic heart disease, rheumatoid arthritis, osteoarthritis,
10 osteoporosis, asthma, multiple sclerosis, neurodegeneration, Alzheimer's, atherosclerosis, stroke and vasculitis.

25. Use according to any of claims 1 to 3 and 21, wherein the condition is selected from Crohn's disease and ulcerative colitis.

26. Use according to any of claims 1 to 3 and 21, wherein the condition is selected
15 from corneal ulceration, retinopathy and surgical wound healing.

27. Use according to any of claims 1 to 3 and 21, wherein the condition is selected from psoriasis, atopic dermatitis, chronic ulcers and epidermolysis bullosa.

28. Use according to any of claims 1 to 3 and 21, wherein the condition is selected from periodontitis and gingivitis.

20 29. Use according to any of claims 1 to 3 and 21, wherein the condition is selected from rhinitis, allergic conjunctivitis, eczema and anaphylaxis.

30. Use according to any of claims 1 to 3 and 21, wherein the condition is selected from restenosis, congestive heart failure, endometriosis, atherosclerosis and endosclerosis.

31. Use according to any of claims 1 to 3 and 21, wherein the condition is selected
25 from pelvic inflammatory disease (PID) and cancer-induced bone resorption.

32. Use according to any of claims 1 to 3 and 21, wherein the condition is selected from age-related macular degeneration.

33. Use according to any of claims 1 to 3 and 21, wherein the condition is a lung disease.

30 34. Use according to claim 33, wherein the condition is selected from cystic fibrosis adult respiratory distress syndrome (ARDS), emphysema, bronchitis obliterans-organising pneumonia (BOOP), idiopathic pulmonary fibrosis (PIF), diffuse alveolar damage,

pulmonary Langerhan's cell granulomatosis, pulmonary lymphangioleiomyomatosis (LAM) and chronic obstructive pulmonary disease (COPD).

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/01076

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C311/21 C07C311/13 C07D295/26 C07D211/96 C07D213/74
 C07D307/81 C07D215/58 A61K31/18 A61K31/4965 A61K31/445
 A61K31/343 A61K31/472 A61P7/00 A61P11/00 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 16503 A (AMERICAN CYANAMID) 23 April 1998 (1998-04-23) page 5 -page 8; claims 1,6-11 ---	1,20
X	US 3 992 441 A (G.F. HELLAND) 16 November 1976 (1976-11-16) column 1 -column 6 ---	6,13
X	GB 1 126 672 A (FARBWERKE HOECHST) 11 September 1968 (1968-09-11) the whole document --- -/--	6,11-13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 August 2000

Date of mailing of the international search report

07/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/01076

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	C.H. ANDREWS. ET AL.: "Experimental chemotherapy of typhus. Antirickettsial action of p-sulphamylbenzamidine and related compounds" PROCEEDINGS OF THE ROYAL SOCIETY OF LONDON, vol. 133, no. 133, December 1946 (1946-12), pages 20-62, XP002100404 The Royal Society, London, GB ISSN: 0080-4649 page 61, line 17 - line 28 ----	6
X	WO 98 38859 A (MONSANTO) 11 September 1998 (1998-09-11) examples 3,7,8 ----- -/--	6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 August 2000

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/01076

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>M.L. HOEFLE, ET AL.: "Diuretics. 4-Substituted 3-sulphamoylbenzoic acid hydrazides" JOURNAL OF MEDICINAL CHEMISTRY, vol. 11, no. 5, September 1968 (1968-09), pages 970-973, XP002144489 American Chemical Society, Washington, DC, US ISSN: 0022-2623 compound 30</p> <p>-----</p>	6,11-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/01076

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9816503 A	23-04-1998	AU 5145898 A	11-05-1998
		BR 9712525 A	19-10-1999
		EP 0938471 A	01-09-1999
		ZA 9709233 A	15-04-1999
US 3992441 A	16-11-1976	US 3843662 A	22-10-1974
		US 4124590 A	07-11-1978
		AR 214849 A	15-08-1979
		AU 6366973 A	19-06-1975
		BE 808939 A	21-06-1974
		CA 1012974 A	28-06-1977
		DE 2363786 A	11-07-1974
		ES 421767 A	01-07-1977
		FR 2211261 A	19-07-1974
		GB 1458029 A	08-12-1976
		IN 139236 A	22-05-1976
		JP 49086522 A	19-08-1974
		JP 58170756 A	07-10-1983
		JP 59024975 B	13-06-1984
		NL 7317455 A	28-06-1974
		US 4377521 A	22-03-1983
		US 4138399 A	06-02-1979
		ZA 7309662 A	29-01-1975
GB 1126672 A		BE 673458 A	08-06-1966
		CH 465633 A	
		CH 470356 A	31-03-1969
		DE 1240873 B	
		DK 114980 B	25-08-1969
		DK 119410 B	28-12-1970
		FI 44620 B	31-08-1971
		FR 5253 M	28-08-1967
		FR 1459530 A	02-02-1967
		IL 24732 A	31-12-1969
		NL 6515475 A	09-06-1966
		SE 345851 B	12-06-1972
		US 3417080 A	17-12-1968
WO 9838859 A	11-09-1998	AU 6447898 A	22-09-1998
		AU 6542498 A	22-09-1998
		AU 6686598 A	22-09-1998
		CN 1253559 T	17-05-2000
		CN 1253474 T	17-05-2000
		CN 1254337 T	24-05-2000
		EP 0983257 A	08-03-2000
		EP 0983258 A	08-03-2000
		EP 0984959 A	15-03-2000
		EP 0973392 A	26-01-2000
		NO 994252 A	02-09-1999
		PL 335732 A	08-05-2000
		WO 9839315 A	11-09-1998
		WO 9839326 A	11-09-1998
		WO 9839316 A	11-09-1998